Genzyme Sues Impax Over Generic Renvela Powder

Law360, New York (July 2, 2010, 11:40 AM EDT) -- Genzyme Corp. has sued Impax Laboratories Inc. in an effort to block a generic version of kidney disease treatment Renvela in powder form, following up on earlier litigation over the tablet form.

Genzyme filed suit Thursday in the U.S. District Court for the District of Maryland, where it already has suits pending against Impax for attempting to make generic tablets of both Renvela and Renagel, a predecessor drug.

Impax stands accused of infringing U.S. Patent Number 5,667,775, which covers both drugs and is also at issue...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.